Herantis Pharma Plc · OMXHEX:HRTIS
Herantis Pharma — Investor Presentation (May 2022)
17 slides from Herantis Pharma's investor presentation, May 2022
Slide 1: Corporate Presentation May 2022
Corporate Presentation May 2022 www.herantis.com © 2014-2022 HERANTIS PHARMA Plc. All rights reserved.
Slide 2: Forward-looking statement
Forward-looking statement This company release includes forward-looking statements which are not historical facts but statements regarding future expectations instead. These forward-looking statements include without limitation, those regarding Herantis’ future financial position and results of oper
Slide 3: Herantis – at a glance
Herantis – at a glance Developing a disease-modifying therapy to Founded in Helsinki, Finland in 2008 with address the unmet clinical need in scientific discoveries out of University of Parkinson’s disease Helsinki Lead asset is HER-096, a small peptidomietic IPO in 2014 and 2019 at First North Nasd
Slide 4: Parkinson's disease is the 2nd most common neurodegenerative disorder
Parkinson’s disease is the 2nd most common neurodegenerative disorder Parkinson’s disease (PD) At time of diagnosis, 50% of dopamine • PD symptoms are caused by degeneration of neurons are estimated to be lost dopaminergic nerve cells in mid brain • PD symptoms are caused by Dopaminergic • Key sympt
Slide 5: HER-096 and CDNF have a unique disease modifying Mechanism of Action
HER-096 and CDNF have a unique disease modifying Mechanism of Action Chronic cellular stress in the brain (ER stress) HER-096 acts on key mechanisms of PD ⍺-synuclein aggregates and other misfolded Neuroinflammation proteins Location of degenerating dopamine producing nerve cells in PD 5 www.heranti
Slide 6: Herantis designed HER-096 to penetrate the BBB
Herantis designed HER-096 to penetrate the BBB • HER-096 is a small synthetic HER-096 peptidomimetic designed after the neuroprotective CDNF protein • HER-096 retains CDNF’s biological activity • HER-096 is designed to reach the brain upon subcutaneous administration, unlike the CDNF protein that re
Slide 7: The Blood Brain Barrier protects the brain from harmful substances
The Blood Brain Barrier (BBB) protects the brain from harmful substances – it is also a major hurdle for the development of pharmaceuticals • BBB blocks entry of most substances from reaching the brain • Pharmaceuticals need to reach a therapeutic concentration in the brain to be effective • Most ph
Slide 8: HER-096 development exploits CDNF data de-risking the development program
HER-096 development exploits CDNF data de-risking the development program HER-096 • Retains CDNF’s activity • Designed to penetrate blood-brain barrier with patient friendly administration HER-096 • First-in-human clinical study planned during 2023 CDNF protein CDNF clinical study Phase 1b clinical
Slide 9: CDNF rescued dopaminergic neurons in a Rhesus monkey PD model
CDNF rescued dopaminergic neurons in a Rhesus monkey PD model Placebo: • Rhesus monkey PD model: – MPTP toxin lesion model in aged Rhesus monkey • Treatment – Three monthly CDNF doses vs placebo – Intracranial administration Main results CDNF: dopaminergic neurons rescued • CDNF doubled the number o
Slide 10: Promising clinical data from CDNF Phase 1b
Promising clinical data from CDNF Phase 1b Good clinical results Promising biomarker data • CDNF was safe and well tolerated in advanced PD patients • DAT PET showed stabilization of dopaminergic activity during CDNF treatment in some patients – potential for • Clinical exploratory endpoints showed
Slide 11: HER-096 animal data confirm its unique MoA and BBB penetration
HER-096 animal data confirm its unique MoA and BBB penetration HER-096’s unique MoA confirmed HER-096 penetrates the BBB in small and large animals in mouse PD model Brain (ISF) Blood (plasma) Small animals Free HER-096 (ng/ml) Following a single subcutaneous injection, the concentration of free HER
Slide 12: Next development milestones for HER-096
Next development milestones for HER-096 Milestone Expected timing • Preclinical safety data (GLP) 2H 2022 • Submission of clinical trial application (CTA) • First HER-096 human dose in Phase 1 study 1H 2023* • HER-096 BBB penetration and safety in human 2H 2023* * Pending funding 12 www.herantis.com
Slide 13: Herantis investment proposition
Herantis investment proposition • HER-096 has the potential to become a therapy for Parkinson’s disease Leading asset with a unique, disease modifying Mechanism of Action • Over 8 million patients globally Market • No disease modifying therapies for Parkinson’s disease today • HER-096 rescues dopami
Slide 14: We have joined Herantis to develop therapies for those who are suffering from PD
We have joined Herantis to develop therapies for those who are suffering from PD Management team Board of Directors Frans Wuite, Tone Kvåle, Antti Vuolanto, D.Sc Timo Veromaa, MD, Hilde Furberg, Mats Thorén, MD, MBA CFO COO PhD, eMBA CEO (interim) Chairman Henri Huttunen, PhD Charlotte Videbæk MD Si
Slide 15: Board and Management have years of experience from companies including
Board and Management have years of experience from companies including: 15 www.herantis.com © 2014-2022 HERANTIS PHARMA Plc. All rights reserved.
Slide 16: Scientific Advisory Board of global industry and academic leaders
Scientific Advisory Board of global industry and academic leaders • Anders Gersel Pedersen, M.D., Ph.D. • Daniele Bravi, M.D., Ph.D. • Chairman of the Board • Specialist Neurologist in movement • Globally renowned and respected expert in CNS disorders drug development. Previously Executive Vice • Re
Slide 17: Contact details
Contact details CEO (interim) Frans Wuite, [email protected] CFO Tone Kvåle, [email protected] COO Antti Vuolanto, [email protected] www.herantis.com © 2014-2022 HERANTIS PHARMA Plc. All rights reserved.